RXST · Rxsight, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $134.48M | $139.93M | $89.08M | $49.01M | $14.68M |
| Cost of Revenue | $31.47M | $40.98M | $35.31M | $27.68M | $12.97M |
| Gross Profit | $103.01M | $98.94M | $53.77M | $21.33M | $1.71M |
| R&D | $38.55M | $34.37M | $29.05M | $25.98M | $21.93M |
| SG&A | $112.65M | $101.43M | $74.80M | $58.66M | $15.18M |
| Total Operating Expenses | $151.20M | $135.80M | $103.85M | $84.65M | $37.12M |
| D&A | $3.27M | $3.58M | $4.08M | $3.88M | $3.85M |
| Operating Income | ($48.19M) | ($36.86M) | ($50.09M) | ($63.32M) | ($35.41M) |
| Interest Expense | $19.0K | $21.0K | $3.31M | $4.95M | $510.0K |
| Income Tax | $66.0K | $50.0K | $20.0K | $9.0K | $57.0K |
| Net Income | ($38.94M) | ($27.45M) | ($48.61M) | ($66.76M) | $27.57M |
| EPS - Basic | ($0.95) | ($0.71) | ($1.41) | ($2.41) | $0.91 |
| EPS - Diluted | ($0.95) | ($0.71) | ($1.41) | ($2.41) | $0.15 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $19.95M | $16.71M | $9.69M | $11.83M | $24.36M |
| Accounts Receivable | $23.38M | $30.05M | $20.28M | $10.96M | $4.86M |
| Inventory | $31.56M | $22.01M | $17.42M | $14.84M | $8.03M |
| Accounts Payable | $5.30M | $4.54M | $3.86M | $2.60M | $1.69M |
| Current Assets | $287.46M | $293.82M | $168.41M | $134.56M | $176.29M |
| Total Assets | $311.81M | $318.56M | $182.55M | $150.16M | $192.72M |
| Current Liabilities | $26.25M | $25.88M | $20.90M | $17.24M | $11.08M |
| Long-term Debt | - | - | $0 | $40.17M | $39.76M |
| Total Liabilities | $36.13M | $37.33M | $22.19M | $60.26M | $54.48M |
| Stockholders' Equity | $275.68M | $281.24M | $160.36M | $89.90M | $138.24M |
| Retained Earnings | ($661.04M) | ($622.10M) | ($594.64M) | ($546.03M) | ($479.28M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($15.51M) | ($16.95M) | ($41.59M) | ($58.85M) | ($35.20M) |
| Investing Cash Flow | $16.89M | ($99.31M) | ($22.13M) | $39.95M | $15.59M |
| Financing Cash Flow | $1.86M | $123.32M | $61.52M | $6.33M | $25.24M |
| CapEx | $3.83M | $5.44M | $4.81M | $2.39M | $2.54M |
| Free Cash Flow | ($19.34M) | ($22.39M) | ($46.41M) | ($61.24M) | ($37.74M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 76.6% | 70.7% | 60.4% | 43.5% | 11.6% |
| Operating margin | -35.8% | -26.3% | -56.2% | -129.2% | -241.3% |
| EBITDA margin | -33.4% | -23.8% | -51.6% | -121.3% | -215.0% |
| Net margin | -29.0% | -19.6% | -54.6% | -136.2% | 187.9% |
| Free cash flow margin | -14.4% | -16.0% | -52.1% | -125.0% | -257.1% |
| FCF / Net income | 0.50 | 0.82 | 0.95 | 0.92 | -1.37 |
| R&D / Revenue | 28.7% | 24.6% | 32.6% | 53.0% | 149.4% |
| SG&A / Revenue | 83.8% | 72.5% | 84.0% | 119.7% | 103.4% |
| Effective tax rate | - | - | - | - | 0.2% |
| Return on assets | -12.5% | -8.6% | -26.6% | -44.5% | 14.3% |
| Return on equity | -14.1% | -9.8% | -30.3% | -74.3% | 19.9% |
| Return on invested capital | - | - | -24.7% | -38.5% | -19.9% |
| Liquidity | |||||
| Current ratio | 10.95 | 11.36 | 8.06 | 7.81 | 15.92 |
| Quick ratio | 9.75 | 10.50 | 7.22 | 6.95 | 15.19 |
| Cash ratio | 0.76 | 0.65 | 0.46 | 0.69 | 2.20 |
| Leverage | |||||
| Debt / Equity | - | - | 0.00 | 0.45 | 0.29 |
| Debt / Assets | - | - | 0.00 | 0.27 | 0.21 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -2536.4x | -1755.1x | -15.1x | -12.8x | -69.4x |
| Equity multiplier | 1.13 | 1.13 | 1.14 | 1.67 | 1.39 |
| Liabilities / Assets | 0.12 | 0.12 | 0.12 | 0.40 | 0.28 |
| Efficiency | |||||
| Asset turnover | 0.43 | 0.44 | 0.49 | 0.33 | 0.08 |
| Inventory turnover | 1.00 | 1.86 | 2.03 | 1.87 | 1.62 |
| Days sales outstanding | 63d | 78d | 83d | 82d | 121d |
| Days inventory outstanding | 366d | 196d | 180d | 196d | 226d |
| Days payable outstanding | 61d | 40d | 40d | 34d | 48d |
| Cash conversion cycle | 368d | 234d | 223d | 243d | 299d |
| Valuation | |||||
| P / E | - | - | - | - | 75.0x |
| P / B | 1.5x | 4.8x | 8.7x | 3.9x | 0.5x |
| P / S | 3.2x | 9.5x | 15.6x | 7.2x | 4.2x |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | -3.9% | 57.1% | 81.8% | 233.9% | - |
| Revenue CAGR (3y) | 40.0% | 112.0% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | 4.1% | 84.0% | 152.1% | 1150.9% | - |
| Operating income growth (YoY) | -30.7% | 26.4% | 20.9% | -78.8% | - |
| Net income growth (YoY) | -41.8% | 43.5% | 27.2% | - | - |
| EPS growth (YoY) | -33.8% | 49.6% | 41.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | 13.6% | 51.8% | 24.2% | -62.3% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -2.0% | 75.4% | 78.4% | -35.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$134.48M totalRxlal$108.06M · 80.4%
LDD$20.67M · 15.4%
Service Warranty Service Contracts And Accessories$5.75M · 4.3%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.96
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Ophthalmic Goods
Comparing RxSight against the 5 most active filers in the same SIC group.